Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float
August 04, 2023 08:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Provides Business Update Following Favorable Comments from US and EU Regulatory Meetings
July 11, 2023 08:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., July 11, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the...
Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th
June 01, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., June 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023 08:30 ET
|
Adial Pharmaceuticals, Inc
Conducted meetings with U.S. and select European regulatory agencies Received Notice of Exercise and upfront cash of $0.45 million from Advocate for the sale of Purnovate assets and business Ended...
Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and Business
May 10, 2023 08:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., May 10, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update
March 30, 2023 16:05 ET
|
Adial Pharmaceuticals, Inc
Secured meetings with U.S. and European regulatory agencies Advancing partnership activities in both the U.S. and Europe Ended 2022 fiscal year with cash and cash equivalents of $4.0...
Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder
March 21, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., March 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th
March 08, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., March 08, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder
March 06, 2023 16:19 ET
|
Adial Pharmaceuticals, Inc
Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European regulatory authoritiesAdial in discussions...
Adial Pharmaceuticals Schedules Business Update Conference Call
March 02, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...